Ricevi le ultime notizie sulle azioni Coherus Oncology con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di CHRS

Ultime notizie per

Coherus BioSciences

Coherus Oncology

Panoramica

Notizie

Utili

Opzioni

Guidance

Valutazioni degli analisti

Insider trading

Vendite allo scoperto

Commerci governativi

Rapporto azionario

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

Comments

Coherus Oncology Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO